Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | TSC1 S331Efs*10 TSC1 LOH |
| Therapy | Buparlisib |
| Indication/Tumor Type | transitional cell carcinoma |
| Response Type | predicted - sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| TSC1 S331Efs*10 TSC1 LOH | transitional cell carcinoma | predicted - sensitive | Buparlisib | Case Reports/Case Series | Actionable | In a Phase II trial, Buparlisib (BKM120) treatment resulted in stable disease in a patient with metastatic urothelial carcinoma harboring TSC1 S331Efs*10 and TSC1 loss of heterozygosity (PMID: 32767682; NCT01551030). | 32767682 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (32767682) | A phase 2 trial of buparlisib in patients with platinum-resistant metastatic urothelial carcinoma. | Full reference... |